Trials / NCT07710196
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Recruiting now Phase 3 Drug / neuroprotection
- Sponsor
- Nacuity Pharmaceuticals, Inc.
- Treatment
- Placebo; NPI-001
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome
- Ages
- 18 Years to no upper limit
- Enrollment
- 80 participants
- Started
- 2026-10
- Main results expected
- 2029-04
- Results posted
- Not yet
- Record last updated
- 2026-10-13
What the study is testing
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are:
Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision.
Participants will:
Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.
Where it runs
United States (1)
- Retina Foundation of the Southwest, Dallas, Texas (recruiting now)